Payment overview · 2025
General Payments
$149.67
9 reported records · 6 companies
Healthcare provider profile · identity verified
Desiree B Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · SALISBURY, NC · NPI 1013903202
Verified facts
What the public records show
CMS Open Payments records show Desiree B Johnson, MD received $149.67 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.70 | 30.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.36 | 23.0% | 2 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $19.61 | 13.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.67 | 12.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.80 | 11.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.53 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $149.67 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.70 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.70 | 3 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 369 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 77 |
| Gabapentin | Gabapentin | 187 | 51 |
| Omeprazole | Omeprazole | 162 | 47 |
| Metformin Hcl | Metformin Hcl | 144 | 40 |
| Lovastatin | Lovastatin | 140 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 40 |
| Carvedilol | Carvedilol | 121 | 31 |
| Furosemide | Furosemide | 121 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 26 |
| Lisinopril | Lisinopril | 105 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 29 |
| Trazodone Hcl | Trazodone Hcl | 94 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 26 |
| Montelukast Sodium | Montelukast Sodium | 87 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 22 |
| Simvastatin | Simvastatin | 80 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 21 |
| Metformin Hcl Er | Metformin Hcl | 75 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 23 |
| Losartan Potassium | Losartan Potassium | 71 | 21 |
| Mounjaro | Tirzepatide | 70 | suppressed |
| Meloxicam | Meloxicam | 68 | 20 |
| Tramadol Hcl | Tramadol Hcl | 66 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 19 |
| Jardiance | Empagliflozin | 62 | 14 |
| Allopurinol | Allopurinol | 59 | 14 |
| Famotidine | Famotidine | 59 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 28 |
| Januvia | Sitagliptin Phosphate | 58 | 11 |
| Celecoxib | Celecoxib | 57 | 12 |
| Ozempic | Semaglutide | 55 | 14 |
| Potassium Chloride | Potassium Chloride | 53 | 18 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Ezetimibe | Ezetimibe | 52 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 52 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Baclofen | Baclofen | 48 | 22 |
| Linzess | Linaclotide | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | 12 |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Nystatin | Nystatin | 43 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | suppressed |
| Eliquis | Apixaban | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Prednisone | Prednisone | 36 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 12 |
| Topiramate | Topiramate | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 22 |
| Torsemide | Torsemide | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 12 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 11 |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 11 |
| Primidone | Primidone | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $149.67 · 9 records | ABBVIE INC. | ABRYSVO, COMIRNATY, Doc Band, JARDIANCE, MOUNJARO, PREVNAR 20, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error